The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The treatment of AML within the United Kingdom NHS framework
Jad Othman, MBBS, King’s College and Guy’s & St Thomas’ NHS Foundation Trust, London, UK, outlines the standard treatment protocol for patients with acute myeloid leukemia (AML) treated within the UK National Health Service (NHS). Patients receive double induction therapy followed by two consolidation treatments, often within the framework of a UK NCRI trial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
